Prothena Q2 Revenue Drops 97%
Prothena (NASDAQ:PRTA), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker-than-expected performance, with GAAP EPS of -2.34 missing the analysts' estimate of -1.25 and a much larger GAAP net loss than anticipated. Reported GAAP revenue was $4.4 million. The company posted a GAAP loss per share of $2.34, missing the estimated GAAP loss of $1.25 per share. The quarter was shaped by the discontinuation of the birtamimab program, a restructuring charge of $32.6 million, and the absence of significant collaboration revenue that boosted results in the prior year.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Prothena develops experimental drugs designed to treat neurodegenerative and amyloid diseases, including Parkinson's, Alzheimer's, and various forms of amyloidosis. Its core approach centers on advancing a pipeline of potential therapies in areas with limited or no effective treatments. Key investigational products include prasinezumab (an antibody for Parkinson’s disease), PRX012 (an antibody for Alzheimer’s disease), and a suite of other candidates targeting protein misfolding disorders.
Source Fool.com
